Literature DB >> 1486913

Diuretics in hypertension: clinical experiences.

V Papademetriou1.   

Abstract

Diuretics have long been used in the treatment of hypertension and are outstandingly efficacious when used either alone or in combination with other antihypertensive compounds. Blood pressure is controlled with diuretics alone in over 50% of patients and in over 80% in combination with other drugs. Thiazide diuretics were used singly and in combination in the early VA Co-operative studies that demonstrated decrease in cardiovascular morbidity with blood pressure control. Subsequent studies have confirmed these early findings and clearly demonstrated that the thiazide diuretics are as effective in lowering blood pressure as other currently available antihypertensive compounds. Diuretics, like all other antihypertensives, have side effects, of which the most important ones are hypokalaemia, alterations of the plasma lipid profile, hyperuricaemia and glucose intolerance. Diuretic-induced hypokalaemia may be hazardous in the presence of digitalis, but does not appear to have any inherent propensity to induce life-threatening arrhythmias. Diuretics remain amongst first-line drugs in the treatment of high blood pressure due to their efficacy, especially in blacks and the elderly, the potentiation of the antihypertensive efficacy of other compounds, their low side effect profile and their low cost.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1486913     DOI: 10.1093/eurheartj/13.suppl_g.92

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  3 in total

1.  Increasing the doses of both diuretics and angiotensin receptor blockers is beneficial in subjects with uncontrolled systolic hypertension.

Authors:  Yves Lacourcière; Luc Poirier; Jean Lefebvre; Stuart A Ross; Frans H Leenen
Journal:  Can J Cardiol       Date:  2010-10       Impact factor: 5.223

Review 2.  Adverse metabolic effects of antihypertensive drugs. Implications for treatment.

Authors:  H G Preuss; J F Burris
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

3.  Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study.

Authors:  Joseph L Izzo; Joel M Neutel; Tonous Silfani; Robert Dubiel; Findlay Walker
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-01       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.